Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides
Sign Up to like & getrecommendations! Published in 2022 at "Proceedings of the National Academy of Sciences of the United States of America"
DOI: 10.1073/pnas.2113180119
Abstract: Significance We report a molecular brush-based oligonucleotide therapeutics platform which uniquely provides conjugated antisense oligonucleotides with binding selectivity, improved pharmacological properties, and an unusual biodistribution profile. These improvements lead to superior in vivo performance compared… read more here.
Keywords: conjugated antisense; targeting oncogenic; antisense oligonucleotides; oncogenic kras ... See more keywords
Therapeutic approaches targeting oncogenic proteins in myeloid leukemia: challenges and perspectives
Sign Up to like & getrecommendations! Published in 2024 at "Expert Opinion on Therapeutic Targets"
DOI: 10.1080/14728222.2024.2443577
Abstract: ABSTRACT Introduction Leukemia is typically categorized into myeloid leukemia and lymphoblastic leukemia based on the origins of leukemic cells. Myeloid leukemia is a group of clonal malignancies characterized by the presence of increased immature myeloid… read more here.
Keywords: proteins myeloid; targeting oncogenic; leukemia; oncogenic proteins ... See more keywords
Abstract 6693: Targeting oncogenic miR-135b in colorectal cancer: Computational modeling and small molecule screening for RNA-based therapy
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-6693
Abstract: Colorectal cancer ranks among the leading causes of cancer-related deaths globally. In this study, we identified miR-135b as a differentially expressed microRNA in colorectal cancer through an analysis of datasets from the Gene Expression Omnibus… read more here.
Keywords: colorectal cancer; cancer; targeting oncogenic; small molecule ... See more keywords
Intracellular targeting of the oncogenic MUC1-C protein with a GO-203 nanoparticle formulation overcomes MCL-1- and BFL-1-mediated resistance in human carcinoma cells.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e14053
Abstract: e14053Background: Aberrant expression of MCL-1 and BFL-1, the pro-survival members of the Bcl-2 family, is a major cause of drug resistance in human cancers. Mucin 1 (MUC1) is a heterodimeric oncop... read more here.
Keywords: mcl bfl; oncogenic muc1; intracellular targeting; targeting oncogenic ... See more keywords
Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms20235999
Abstract: Colorectal cancer (CRC) is a kind of solid tumor and the third most common cancer type in the world. It is a heterogeneous disease characterized by genetic and epigenetic aberrations. The TP53 mutation is the… read more here.
Keywords: solid tumors; colorectal cancer; p53 mutants; p53 ... See more keywords
Clinical and Preclinical Targeting of Oncogenic Pathways in PDAC: Targeted Therapeutic Approaches for the Deadliest Cancer
Sign Up to like & getrecommendations! Published in 2024 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms25052860
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related death worldwide. It is commonly diagnosed in advanced stages and therapeutic interventions are typically constrained to systemic chemotherapy, which yields only modest clinical… read more here.
Keywords: cancer; clinical preclinical; targeting oncogenic; preclinical targeting ... See more keywords